$24.57 Million in Sales Expected for Guardant Health Inc (GH) This Quarter

Share on StockTwits

Wall Street brokerages expect Guardant Health Inc (NASDAQ:GH) to report sales of $24.57 million for the current quarter, according to Zacks. Four analysts have made estimates for Guardant Health’s earnings. The highest sales estimate is $26.58 million and the lowest is $20.99 million. The company is expected to announce its next quarterly earnings results on Monday, February 18th.

On average, analysts expect that Guardant Health will report full-year sales of $83.43 million for the current financial year, with estimates ranging from $82.50 million to $84.01 million. For the next financial year, analysts forecast that the company will report sales of $116.02 million, with estimates ranging from $111.69 million to $120.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Guardant Health.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Monday, November 19th. The company reported ($1.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($1.65). The firm had revenue of $21.70 million for the quarter, compared to the consensus estimate of $17.44 million. The firm’s revenue was up 95.5% compared to the same quarter last year.

A number of equities research analysts have commented on the stock. Cowen assumed coverage on shares of Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. Leerink Swann restated an “outperform” rating on shares of Guardant Health in a report on Monday, October 29th. William Blair assumed coverage on shares of Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Guardant Health in a report on Monday, October 29th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, Bank of America assumed coverage on shares of Guardant Health in a report on Monday, October 29th. They issued a “neutral” rating and a $37.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Guardant Health currently has an average rating of “Buy” and an average target price of $39.50.

Shares of GH traded up $1.40 during trading hours on Friday, hitting $42.94. 380,395 shares of the stock were exchanged, compared to its average volume of 442,587. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $49.55.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

See Also: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate Manitowoc Company Inc  Will Post Quarterly Sales of $487.25 Million
Zacks: Analysts Anticipate Manitowoc Company Inc Will Post Quarterly Sales of $487.25 Million
Memetic / PepeCoin Price Tops $0.0241
Memetic / PepeCoin Price Tops $0.0241
$606.24 Million in Sales Expected for Kennametal Inc.  This Quarter
$606.24 Million in Sales Expected for Kennametal Inc. This Quarter
$60.09 Million in Sales Expected for Navios Maritime Partners L.P.  This Quarter
$60.09 Million in Sales Expected for Navios Maritime Partners L.P. This Quarter
AXT  Downgraded by Zacks Investment Research to “Sell”
AXT Downgraded by Zacks Investment Research to “Sell”
Zacks Investment Research Lowers ASSD BRIT FOODS/ADR  to Sell
Zacks Investment Research Lowers ASSD BRIT FOODS/ADR to Sell


Leave a Reply

© 2006-2019 Ticker Report